Acticor Biotech Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Employees
-
31
- Latest Deal Type
-
Liquidation
Acticor Biotech General Information
Description
Developer of a stroke therapeutics biotechnology intended for the treatment of acute thrombotic diseases. The Company focuses on developing a treatment for thrombotic diseases, with a primary focus on acute ischemic stroke.
Contact Information
Website
www.acticor-biotech.comCorporate Office
- Wojo Building
- 82 avenue du Maine
- 75014 Paris
- France
Corporate Office
- Wojo Building
- 82 avenue du Maine
- 75014 Paris
- France
Acticor Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Bankruptcy: Liquidation | 02-Jan-2025 | Completed | Bankruptcy: Liquidation | |||
| 13. PIPE | 15-Mar-2024 | Completed | Generating Revenue | |||
| 12. 2PO | 15-Mar-2024 | Completed | Generating Revenue | |||
| 11. PIPE | 28-Nov-2023 | Completed | Generating Revenue | |||
| 10. 2PO | 28-Nov-2023 | Completed | Generating Revenue | |||
| 9. PIPE | 09-Mar-2023 | Completed | Generating Revenue | |||
| 8. IPO | 01-Nov-2021 | Completed | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC | 07-Sep-2021 | Completed | Clinical Trials - Phase 3 | |||
| 6. Accelerator/Incubator | 01-Jan-2020 | $29.9M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 06-Nov-2019 | $26.3M | $29.9M | Completed | Clinical Trials - Phase 2 |
Acticor Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | 28,039 | $1.177398 | $64.76 | $64.76 | 1x | $64.76 | 6.7% | |
| Ordinary | 17,552 | $1.177398 | $44.74 | $44.74 | 1x | $44.74 | 4.2% |
Acticor Biotech Comparisons
Industry
Financing
Details
Acticor Biotech Competitors (8)
One of Acticor Biotech’s 8 competitors is Anthos Therapeutics, a Formerly PE-Backed company based in East Hanover, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Anthos Therapeutics | Formerly PE-Backed | East Hanover, NJ | ||||
| Aronora | Venture Capital-Backed | Portland, OR | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Acticor Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Acticor Biotech Patents
Acticor Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4556492-A1 | Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects | Inactive | 14-Nov-2023 | ||
| WO-2025104204-A1 | Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects | Inactive | 14-Nov-2023 | ||
| EP-4482863-A1 | Treatment of cardiovascular diseases using anti-human gpvi antibodies | Inactive | 21-Feb-2022 | ||
| US-20250154252-A1 | Treatment of cardiovascular diseases using anti-human gpvi antibodies | Pending | 21-Feb-2022 | ||
| WO-2023156683-A1 | Treatment of cardiovascular diseases using anti-human gpvi antibodies | Inactive | 21-Feb-2022 | C07K16/2803 |
Acticor Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Acticor Biotech Acquisitions (1)
Acticor Biotech’s most recent deal was a Merger/Acquisition with AVCare. The deal was made on 06-Nov-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AVCare | 06-Nov-2019 | Merger/Acquisition | Diagnostic Equipment |
Acticor Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Acticor Biotech FAQs
-
When was Acticor Biotech founded?
Acticor Biotech was founded in 2013.
-
Where is Acticor Biotech headquartered?
Acticor Biotech is headquartered in Paris, France.
-
What is the size of Acticor Biotech?
Acticor Biotech has 31 total employees.
-
What industry is Acticor Biotech in?
Acticor Biotech’s primary industry is Drug Discovery.
-
Is Acticor Biotech a private or public company?
Acticor Biotech is a Private company.
-
What is Acticor Biotech’s current revenue?
The current revenue for Acticor Biotech is .
-
How much funding has Acticor Biotech raised over time?
Acticor Biotech has raised $76.9M.
-
Who are Acticor Biotech’s competitors?
Anthos Therapeutics, Aronora, Agenus, Agios Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 8 competitors of Acticor Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
